Olaratumab

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1] It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses"). Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 M... [wikipedia]